ANDA 40069, held by Bausch & Lomb. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 40069 (Dexamethasone Sodium Phosphate), held by Bausch & Lomb, was first approved by FDA on Jul 26, 1996, with 13 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic: Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 26, 1996 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 0.1% PHOSPHATE · solution/drops;ophthalmic, otic | Dexamethasone Sodium Phosphate | Rx |
| Dec 23, 2002 | Supplement 15Manufacturing | Approved | None posted |
| Nov 27, 2001 | Supplement 14Manufacturing | Approved | None posted |
| Apr 30, 2001 | Supplement 13Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 12Manufacturing | Approved | None posted |
| Jun 27, 2000 | Supplement 11Manufacturing | Approved | None posted |
| May 18, 2000 | Supplement 8Manufacturing | Approved | None posted |
| Apr 28, 2000 | Supplement 9Manufacturing | Approved | None posted |
| Jun 7, 1999 | Supplement 7Manufacturing | Approved | None posted |
| Nov 19, 1998 | Supplement 5Manufacturing | Approved | None posted |
| Aug 27, 1998 | Supplement 6Manufacturing | Approved | None posted |
| Mar 13, 1998 | Supplement 2Manufacturing | Approved | None posted |
| Feb 10, 1998 | Supplement 3Manufacturing | Approved | None posted |
| May 16, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Jul 26, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters